Skip to main content
Top
Published in: Trials 1/2012

Open Access 01-12-2012 | Research

Removing barriers to participation in clinical trials, a conceptual framework and retrospective chart review study

Authors: Norma F Kanarek, Marty S Kanarek, Dare Olatoye, Michael A Carducci

Published in: Trials | Issue 1/2012

Login to get access

Abstract

Background

Enrollment in interventional therapeutic clinical trials is a small fraction of all patients who might participate given reasonable access.

Methods

A hierarchical approach is utilized in measuring staged participation from trial availability to patient enrollment. Our framework suggests that concern for justice comes in the design and eligibility criteria for clinical trials; attention to beneficence is given in the eligibility and physician triage stages. The remaining four stages rely on respect for persons. An example is given where reasons for nonparticipation or barriers to participation in prostate cancer clinical trials are examined within the framework. In addition, medical oncology patients with an initial six month consultation are tracked from one stage to the next by race using the framework to assess participation comparability.

Results

We illustrated seven transitions from being a patient to enrollment in a clinical trial in a small study of prostate cancer cases who consulted SKCCC Medical Oncology Department in early 2010. Pilot data suggest transition probabilities as follows: 65% availability, 84% eligibility, 92% patient triage, 89% trials discussed, 45% patient interested, 63% patient consented, and 92% patient enrolled. The average transition probability was 77.7%. The average transition probability, patient-trial-fit was 50%; opportunity was 51%, and acceptance was 66.7%. Trial availability, patient interest and patient consented were three transitions that were below the average; none were statistically significant.

Conclusions

The framework may serve to streamline comprehensive reporting of clinical trial participation to the benefit of patients and the ethical conduct of clinical trials.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sateren WB, Trimble EL, Abrams J, Brawley O, Breen N, Ford L, McCabe M, Kaplan R, Smith M, Ungerleider R, Christian MC: How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J Clin Oncol. 2002, 20: 2109-2117.CrossRefPubMed Sateren WB, Trimble EL, Abrams J, Brawley O, Breen N, Ford L, McCabe M, Kaplan R, Smith M, Ungerleider R, Christian MC: How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J Clin Oncol. 2002, 20: 2109-2117.CrossRefPubMed
2.
go back to reference Al-Refaie WB, Vickers SM, Zhong W, Parsons H, Rothenberger D, Habermann EB: Cancer trials versus the real world in the United States. Ann Surg. 2011, 254: 438-443.CrossRefPubMed Al-Refaie WB, Vickers SM, Zhong W, Parsons H, Rothenberger D, Habermann EB: Cancer trials versus the real world in the United States. Ann Surg. 2011, 254: 438-443.CrossRefPubMed
3.
go back to reference Baquet CR, Ellison GL, Mishra SI: Analysis of Maryland cancer patient participation in national cancer institute-supported cancer treatment clinical trials. J Clin Oncol. 2008, 26: 3380-3386.CrossRefPubMedPubMedCentral Baquet CR, Ellison GL, Mishra SI: Analysis of Maryland cancer patient participation in national cancer institute-supported cancer treatment clinical trials. J Clin Oncol. 2008, 26: 3380-3386.CrossRefPubMedPubMedCentral
4.
go back to reference Tejeda HA, Green SB, Trimble EL, Ford L, High JL, Ungerleider RS, Friedman MA, Brawley OW: Representation of African-Americans, Hispanics, and whites in national cancer institute cancer treatment trials. J Natl Cancer Inst. 1996, 88: 812-816.CrossRefPubMed Tejeda HA, Green SB, Trimble EL, Ford L, High JL, Ungerleider RS, Friedman MA, Brawley OW: Representation of African-Americans, Hispanics, and whites in national cancer institute cancer treatment trials. J Natl Cancer Inst. 1996, 88: 812-816.CrossRefPubMed
5.
go back to reference Kanarek NF, Tsai HL, Metzger-Gaud S, Damron D, Guseynova A, Klamerus JF, Rudin CM: Geographic proximity and racial disparities in cancer clinical trial participation. J Natl Compr Canc Netw. 2010, 8: 1343-1351.PubMedPubMedCentral Kanarek NF, Tsai HL, Metzger-Gaud S, Damron D, Guseynova A, Klamerus JF, Rudin CM: Geographic proximity and racial disparities in cancer clinical trial participation. J Natl Compr Canc Netw. 2010, 8: 1343-1351.PubMedPubMedCentral
6.
go back to reference Onega T, Duell EJ, Shi X, Wang D, Demidenko E, Goodman D: Geographic access to cancer care in the U.S. Cancer. 2008, 112: 909-918.CrossRefPubMed Onega T, Duell EJ, Shi X, Wang D, Demidenko E, Goodman D: Geographic access to cancer care in the U.S. Cancer. 2008, 112: 909-918.CrossRefPubMed
7.
go back to reference Su SC, Kanarek N, Fox MG, Guseynova A, Crow S, Piantadosi S: Spatial analyses identify the geographic source of patients at a National Cancer Institute Comprehensive Cancer Center. Clin Cancer Res. 2010, 16: 1065-1072.CrossRefPubMed Su SC, Kanarek N, Fox MG, Guseynova A, Crow S, Piantadosi S: Spatial analyses identify the geographic source of patients at a National Cancer Institute Comprehensive Cancer Center. Clin Cancer Res. 2010, 16: 1065-1072.CrossRefPubMed
8.
go back to reference Martel CL, Li Y, Beckett L, Chew H, Christensen S, Davies A, Lam KS, Lau DH, Meyers FJ, O'Donnell RT, Richman C, Scudder S, Tanaka M, Tuscano J, Welborn J, Wun T, Gandara DR, Lara PN: An evaluation of barriers to accrual in the era of legislation requiring insurance coverage of cancer clinical trial costs in California. Cancer J. 2004, 10: 294-300.CrossRefPubMed Martel CL, Li Y, Beckett L, Chew H, Christensen S, Davies A, Lam KS, Lau DH, Meyers FJ, O'Donnell RT, Richman C, Scudder S, Tanaka M, Tuscano J, Welborn J, Wun T, Gandara DR, Lara PN: An evaluation of barriers to accrual in the era of legislation requiring insurance coverage of cancer clinical trial costs in California. Cancer J. 2004, 10: 294-300.CrossRefPubMed
9.
go back to reference Castel P, Negrier S, Boissel JP: Why don't cancer patients enter clinical trials?. A review. Eur J Cancer. 2006, 42: 1744-1748.CrossRefPubMed Castel P, Negrier S, Boissel JP: Why don't cancer patients enter clinical trials?. A review. Eur J Cancer. 2006, 42: 1744-1748.CrossRefPubMed
10.
go back to reference Grunfeld E, Zitzelsberger L, Coristine M, Aspelund F: Barriers and facilitators to enrollment in cancer clinical trials: qualitative study of the perspectives of clinical research associates. Cancer. 2002, 95: 1577-1583.CrossRefPubMed Grunfeld E, Zitzelsberger L, Coristine M, Aspelund F: Barriers and facilitators to enrollment in cancer clinical trials: qualitative study of the perspectives of clinical research associates. Cancer. 2002, 95: 1577-1583.CrossRefPubMed
11.
go back to reference Lara PN, Paterniti DA, Chiechi C, Turrell C, Morain C, Horan N, Montell L, Gonzalez J, Davis S, Umutyan A, Martel CL, Gandara DR, Wun T, Beckett LA, Chen MS: Evaluation of factors affecting awareness of and willingness to participate in cancer clinical trials. J Clin Oncol. 2005, 23: 9282-9289.CrossRefPubMed Lara PN, Paterniti DA, Chiechi C, Turrell C, Morain C, Horan N, Montell L, Gonzalez J, Davis S, Umutyan A, Martel CL, Gandara DR, Wun T, Beckett LA, Chen MS: Evaluation of factors affecting awareness of and willingness to participate in cancer clinical trials. J Clin Oncol. 2005, 23: 9282-9289.CrossRefPubMed
13.
go back to reference Lara PN, Higdon R, Lim N, Kwan K, Tanaka M, Lau DH, Wun T, Welborn J, Meyers FJ, Christensen S, O’Donnell R, Richman C, Scudder SA, Tuscano J, Gandara DR, Lam KS: Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol. 2001, 19: 1728-1733.PubMed Lara PN, Higdon R, Lim N, Kwan K, Tanaka M, Lau DH, Wun T, Welborn J, Meyers FJ, Christensen S, O’Donnell R, Richman C, Scudder SA, Tuscano J, Gandara DR, Lam KS: Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol. 2001, 19: 1728-1733.PubMed
14.
go back to reference Schiller JH: Study design issues and early stage non-small cell lung cancer. Clin Cancer Res. 2005, 11: 5030s-5032s.CrossRefPubMed Schiller JH: Study design issues and early stage non-small cell lung cancer. Clin Cancer Res. 2005, 11: 5030s-5032s.CrossRefPubMed
15.
go back to reference Go RS, Frisby KA, Lee JA, Mathiason MA, Meyer CM, Ostern JL, Walther SM, Schroeder JE, Meyer LA, Umberger KE: Clinical trial accrual among new cancer patients at a community-based cancer center. Cancer. 2006, 106: 426-433.CrossRefPubMed Go RS, Frisby KA, Lee JA, Mathiason MA, Meyer CM, Ostern JL, Walther SM, Schroeder JE, Meyer LA, Umberger KE: Clinical trial accrual among new cancer patients at a community-based cancer center. Cancer. 2006, 106: 426-433.CrossRefPubMed
16.
go back to reference Proctor JW, Martz E, Schenken LL, Rainville R, Marlowe U: A screening tool to enhance clinical trial participation at a community center involved in a radiation oncology disparities program. J Oncol Pract. 2011, 7: 161-164.CrossRefPubMedPubMedCentral Proctor JW, Martz E, Schenken LL, Rainville R, Marlowe U: A screening tool to enhance clinical trial participation at a community center involved in a radiation oncology disparities program. J Oncol Pract. 2011, 7: 161-164.CrossRefPubMedPubMedCentral
17.
go back to reference Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, Gotzsche PC, Lang T: The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med. 2001, 134: 663-694.CrossRefPubMed Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, Gotzsche PC, Lang T: The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med. 2001, 134: 663-694.CrossRefPubMed
18.
go back to reference Unger JM, Coltman CA, Crowley JJ, Hutchins LF, Martino S, Livingston RB, Macdonald JS, Blanke CD, Gandara DR, Crawford ED, Albain KS: Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trials. J Clin Oncol. 2006, 24: 141-144.CrossRefPubMed Unger JM, Coltman CA, Crowley JJ, Hutchins LF, Martino S, Livingston RB, Macdonald JS, Blanke CD, Gandara DR, Crawford ED, Albain KS: Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trials. J Clin Oncol. 2006, 24: 141-144.CrossRefPubMed
19.
go back to reference The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research: The Belmont report: ethical principles and guidelines for the protection of human subjects of research. 1979, Washington, DC: United States Department of Health, Education, and Welfare The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research: The Belmont report: ethical principles and guidelines for the protection of human subjects of research. 1979, Washington, DC: United States Department of Health, Education, and Welfare
20.
21.
go back to reference Brawley OW: The study of accrual to clinical trials: can we learn from studying who enters our studies?. J Clin Oncol. 2004, 22: 2039-2040.CrossRefPubMed Brawley OW: The study of accrual to clinical trials: can we learn from studying who enters our studies?. J Clin Oncol. 2004, 22: 2039-2040.CrossRefPubMed
22.
go back to reference Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Vollmer R, Wilding G: Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999, 17: 3461-3467.PubMed Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Vollmer R, Wilding G: Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999, 17: 3461-3467.PubMed
23.
go back to reference Scher HI, Eisenberger M, D'Amico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, Agus D, Slovin SF, Heller G, Kelly W, Lange PH, Petrylak D, Berg W, Higano C, Wilding G, Moul JW, Partin AN, Logothetis C, Soule HR: Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 2004, 22: 537-556.CrossRefPubMed Scher HI, Eisenberger M, D'Amico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, Agus D, Slovin SF, Heller G, Kelly W, Lange PH, Petrylak D, Berg W, Higano C, Wilding G, Moul JW, Partin AN, Logothetis C, Soule HR: Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 2004, 22: 537-556.CrossRefPubMed
24.
go back to reference Simon MS, Du W, Flaherty L, Philip PA, Lorusso P, Miree C, Smith D, Brown DR: Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center. J Clin Oncol. 2004, 22: 2046-2052.CrossRefPubMed Simon MS, Du W, Flaherty L, Philip PA, Lorusso P, Miree C, Smith D, Brown DR: Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center. J Clin Oncol. 2004, 22: 2046-2052.CrossRefPubMed
25.
26.
go back to reference Kemeny MM, Peterson BL, Kornblith AB, Muss HB, Wheeler J, Levine E, Bartlett N, Fleming G, Cohen HJ: Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol. 2003, 21: 2268-2275.CrossRefPubMed Kemeny MM, Peterson BL, Kornblith AB, Muss HB, Wheeler J, Levine E, Bartlett N, Fleming G, Cohen HJ: Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol. 2003, 21: 2268-2275.CrossRefPubMed
27.
go back to reference Sheldon JM, Fetting JH, Siminoff LA: Offering the option of randomized clinical trials to cancer patients who overestimate their prognoses with standard therapies. Cancer Invest. 1993, 11: 57-62.CrossRefPubMed Sheldon JM, Fetting JH, Siminoff LA: Offering the option of randomized clinical trials to cancer patients who overestimate their prognoses with standard therapies. Cancer Invest. 1993, 11: 57-62.CrossRefPubMed
28.
go back to reference Miller FG, Rosenstein DL: The therapeutic orientation to clinical trials. N Engl J Med. 2003, 348: 1383-1386.CrossRefPubMed Miller FG, Rosenstein DL: The therapeutic orientation to clinical trials. N Engl J Med. 2003, 348: 1383-1386.CrossRefPubMed
29.
go back to reference Mannel RS, Walker JL, Gould N, Scribner DR, Kamelle S, Tillmanns T, McMeekin DS, Gold MA: Impact of individual physicians on enrollment of patients into clinical trials. Am J Clin Oncol. 2003, 26: 171-173.CrossRefPubMed Mannel RS, Walker JL, Gould N, Scribner DR, Kamelle S, Tillmanns T, McMeekin DS, Gold MA: Impact of individual physicians on enrollment of patients into clinical trials. Am J Clin Oncol. 2003, 26: 171-173.CrossRefPubMed
30.
go back to reference Meropol NJ, Egleston BL, Buzaglo JS, Benson AB, Cegala DJ, Diefenbach MA, Fleisher L, Miller SM, Sulmasy DP, Weinfurt KP: Cancer patient preferences for quality and length of life. Cancer. 2008, 113: 3459-3466.CrossRefPubMedPubMedCentral Meropol NJ, Egleston BL, Buzaglo JS, Benson AB, Cegala DJ, Diefenbach MA, Fleisher L, Miller SM, Sulmasy DP, Weinfurt KP: Cancer patient preferences for quality and length of life. Cancer. 2008, 113: 3459-3466.CrossRefPubMedPubMedCentral
31.
go back to reference Stiles CR, Johnson L, Whyte D, Nergaard TH, Gardner J, Wu J: Does increased patient awareness improve accrual into cancer-related clinical trials?. Cancer Nurs. 2011, 34: E13-19.CrossRefPubMed Stiles CR, Johnson L, Whyte D, Nergaard TH, Gardner J, Wu J: Does increased patient awareness improve accrual into cancer-related clinical trials?. Cancer Nurs. 2011, 34: E13-19.CrossRefPubMed
32.
go back to reference Shannon-Dorcy K, Drevdahl DJ: "I had already made Up My mind": patients and caregivers' perspectives on making the decision to participate in research at a US cancer referral center. Cancer Nurs. 2011, 34: 428-433.CrossRefPubMed Shannon-Dorcy K, Drevdahl DJ: "I had already made Up My mind": patients and caregivers' perspectives on making the decision to participate in research at a US cancer referral center. Cancer Nurs. 2011, 34: 428-433.CrossRefPubMed
33.
go back to reference Weinfurt KP, Castel LD, Li Y, Sulmasy DP, Balshem AM, Benson AB, Burnett CB, Gaskin DJ, Marshall JL, Slater EF, Schulman KA, Meropol NJ: The correlation between patient characteristics and expectations of benefit from phase I clinical trials. Cancer. 2003, 98: 166-175.CrossRefPubMed Weinfurt KP, Castel LD, Li Y, Sulmasy DP, Balshem AM, Benson AB, Burnett CB, Gaskin DJ, Marshall JL, Slater EF, Schulman KA, Meropol NJ: The correlation between patient characteristics and expectations of benefit from phase I clinical trials. Cancer. 2003, 98: 166-175.CrossRefPubMed
34.
go back to reference Biedrzycki BA: Factors and outcomes of decision making for cancer clinical trial participation. Oncol Nurs Forum. 2011, 38: 542-552.CrossRefPubMed Biedrzycki BA: Factors and outcomes of decision making for cancer clinical trial participation. Oncol Nurs Forum. 2011, 38: 542-552.CrossRefPubMed
35.
go back to reference Brown RF, Butow PN, Butt DG, Moore AR, Tattersall MH: Developing ethical strategies to assist oncologists in seeking informed consent to cancer clinical trials. Soc Sci Med. 2004, 58: 379-390.CrossRefPubMed Brown RF, Butow PN, Butt DG, Moore AR, Tattersall MH: Developing ethical strategies to assist oncologists in seeking informed consent to cancer clinical trials. Soc Sci Med. 2004, 58: 379-390.CrossRefPubMed
36.
go back to reference Kass N, Taylor H, Fogarty L, Sugarman J, Goodman SN, Goodwin-Landher A, Carducci M, Hurwitz H: Purpose and benefits of early phase cancer trials: what do oncologists say? what do patients hear?. J Empir Res Hum Res Ethics. 2008, 3: 57-68.CrossRefPubMedPubMedCentral Kass N, Taylor H, Fogarty L, Sugarman J, Goodman SN, Goodwin-Landher A, Carducci M, Hurwitz H: Purpose and benefits of early phase cancer trials: what do oncologists say? what do patients hear?. J Empir Res Hum Res Ethics. 2008, 3: 57-68.CrossRefPubMedPubMedCentral
37.
go back to reference Kass NE, Sugarman J, Medley AM, Fogarty LA, Taylor HA, Daugherty CK, Emerson MR, Goodman SN, Hlubocky FJ, Hurwitz HI, Carducci M, Goodwin-Landher A: An intervention to improve cancer patients' understanding of early-phase clinical trials. IRB. 2009, 31: 1-10.PubMedPubMedCentral Kass NE, Sugarman J, Medley AM, Fogarty LA, Taylor HA, Daugherty CK, Emerson MR, Goodman SN, Hlubocky FJ, Hurwitz HI, Carducci M, Goodwin-Landher A: An intervention to improve cancer patients' understanding of early-phase clinical trials. IRB. 2009, 31: 1-10.PubMedPubMedCentral
38.
go back to reference Ruckdeschel JC, Albrecht TL, Blanchard C, Hemmick RM: Communication, accrual to clinical trials, and the physician-patient relationship: implications for training programs. J Cancer Educ. 1996, 11: 73-79.PubMed Ruckdeschel JC, Albrecht TL, Blanchard C, Hemmick RM: Communication, accrual to clinical trials, and the physician-patient relationship: implications for training programs. J Cancer Educ. 1996, 11: 73-79.PubMed
39.
go back to reference Meropol NJ, Buzaglo JS, Millard J, Damjanov N, Miller SM, Ridgway C, Ross EA, Sprandio JD, Watts P: Barriers to clinical trial participation as perceived by oncologists and patients. J Natl Compr Canc Netw. 2007, 5: 655-664.PubMed Meropol NJ, Buzaglo JS, Millard J, Damjanov N, Miller SM, Ridgway C, Ross EA, Sprandio JD, Watts P: Barriers to clinical trial participation as perceived by oncologists and patients. J Natl Compr Canc Netw. 2007, 5: 655-664.PubMed
40.
go back to reference Sulmasy DP, Astrow AB, He MK, Seils DM, Meropol NJ, Micco E, Weinfurt KP: The culture of faith and hope: patients' justifications for their high estimations of expected therapeutic benefit when enrolling in early phase oncology trials. Cancer. 2010, 116: 3702-3711.CrossRefPubMedPubMedCentral Sulmasy DP, Astrow AB, He MK, Seils DM, Meropol NJ, Micco E, Weinfurt KP: The culture of faith and hope: patients' justifications for their high estimations of expected therapeutic benefit when enrolling in early phase oncology trials. Cancer. 2010, 116: 3702-3711.CrossRefPubMedPubMedCentral
41.
go back to reference Rasco DW, Xie Y, Yan J, Sayne JR, Skinner CS, Dowell JE, Gerber DE: The impact of consenter characteristics and experience on patient interest in clinical research. Oncologist. 2009, 14: 468-475.CrossRefPubMed Rasco DW, Xie Y, Yan J, Sayne JR, Skinner CS, Dowell JE, Gerber DE: The impact of consenter characteristics and experience on patient interest in clinical research. Oncologist. 2009, 14: 468-475.CrossRefPubMed
42.
go back to reference Lee MM, Chamberlain RM, Catchatourian R, Hiang J, Kopnick M, Ray P, Vijayakumar S: Social factors affecting interest in participating in a prostate cancer chemoprevention trial. J Cancer Educ. 1999, 14: 88-92.PubMed Lee MM, Chamberlain RM, Catchatourian R, Hiang J, Kopnick M, Ray P, Vijayakumar S: Social factors affecting interest in participating in a prostate cancer chemoprevention trial. J Cancer Educ. 1999, 14: 88-92.PubMed
43.
go back to reference Sabesan S, Burgher B, Buettner P, Piliouras P, Otty Z, Varma S, Thaker D: Attitudes, knowledge and barriers to participation in cancer clinical trials among rural and remote patients. Asia Pac J Clin Oncol. 2011, 7: 27-33.CrossRefPubMed Sabesan S, Burgher B, Buettner P, Piliouras P, Otty Z, Varma S, Thaker D: Attitudes, knowledge and barriers to participation in cancer clinical trials among rural and remote patients. Asia Pac J Clin Oncol. 2011, 7: 27-33.CrossRefPubMed
44.
go back to reference Stepan KA, Gonzalez AP, Dorsey VS, Frye DK, Pyle ND, Smith RF, Throckmorton TA, Villejo LA, Cantor SB: Recommendations for enhancing clinical trials education: a review of the literature. J Cancer Educ. 2011, 26: 64-71.CrossRefPubMed Stepan KA, Gonzalez AP, Dorsey VS, Frye DK, Pyle ND, Smith RF, Throckmorton TA, Villejo LA, Cantor SB: Recommendations for enhancing clinical trials education: a review of the literature. J Cancer Educ. 2011, 26: 64-71.CrossRefPubMed
45.
go back to reference Daugherty CK: Impact of therapeutic research on informed consent and the ethics of clinical trials: a medical oncology perspective. J Clin Oncol. 1999, 17: 1601-1617.PubMed Daugherty CK: Impact of therapeutic research on informed consent and the ethics of clinical trials: a medical oncology perspective. J Clin Oncol. 1999, 17: 1601-1617.PubMed
46.
go back to reference Mulhall JP, Montorsi F: Evaluating preference trials of oral phosphodiesterase 5 inhibitors for erectile dysfunction. Eur Urol. 2006, 49: 30-37.CrossRefPubMed Mulhall JP, Montorsi F: Evaluating preference trials of oral phosphodiesterase 5 inhibitors for erectile dysfunction. Eur Urol. 2006, 49: 30-37.CrossRefPubMed
47.
go back to reference Wolf AM, Nasser JF, Schorling JB: The impact of informed consent on patient interest in prostate-specific antigen screening. Arch Intern Med. 1996, 156: 1333-1336.CrossRefPubMed Wolf AM, Nasser JF, Schorling JB: The impact of informed consent on patient interest in prostate-specific antigen screening. Arch Intern Med. 1996, 156: 1333-1336.CrossRefPubMed
48.
go back to reference Miller FG, Joffe S: Balancing access and evaluation in the approval of new cancer drugs. JAMA. 2011, 305: 2345-2346.CrossRefPubMed Miller FG, Joffe S: Balancing access and evaluation in the approval of new cancer drugs. JAMA. 2011, 305: 2345-2346.CrossRefPubMed
49.
go back to reference Agrawal M, Grady C, Fairclough DL, Meropol NJ, Maynard K, Emanuel EJ: Patients' decision-making process regarding participation in phase I oncology research. J Clin Oncol. 2006, 24: 4479-4484.CrossRefPubMed Agrawal M, Grady C, Fairclough DL, Meropol NJ, Maynard K, Emanuel EJ: Patients' decision-making process regarding participation in phase I oncology research. J Clin Oncol. 2006, 24: 4479-4484.CrossRefPubMed
50.
go back to reference Klamerus JF, Bruinooge SS, Ye X, Klamerus ML, Damron D, Lansey D, Lowery JC, Diaz LA, Ford JG, Kanarek N, Rudin CM: The impact of insurance on access to cancer clinical trials at a comprehensive cancer center. Clin Cancer Res. 2010, 16: 5997-6003.CrossRefPubMedPubMedCentral Klamerus JF, Bruinooge SS, Ye X, Klamerus ML, Damron D, Lansey D, Lowery JC, Diaz LA, Ford JG, Kanarek N, Rudin CM: The impact of insurance on access to cancer clinical trials at a comprehensive cancer center. Clin Cancer Res. 2010, 16: 5997-6003.CrossRefPubMedPubMedCentral
51.
go back to reference Mills EJ, Seely D, Rachlis B, Griffith L, Wu P, Wilson K, Ellis P, Wright JR: Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors. Lancet Oncol. 2006, 7: 141-148.CrossRefPubMed Mills EJ, Seely D, Rachlis B, Griffith L, Wu P, Wilson K, Ellis P, Wright JR: Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors. Lancet Oncol. 2006, 7: 141-148.CrossRefPubMed
52.
go back to reference Schutta KM, Burnett CB: Factors that influence a patient's decision to participate in a phase I cancer clinical trial. Oncol Nurs Forum. 2000, 27: 1435-1438.PubMed Schutta KM, Burnett CB: Factors that influence a patient's decision to participate in a phase I cancer clinical trial. Oncol Nurs Forum. 2000, 27: 1435-1438.PubMed
53.
go back to reference Wright JR, Crooks D, Ellis PM, Mings D, Whelan TJ: Factors that influence the recruitment of patients to phase III studies in oncology: the perspective of the clinical research associate. Cancer. 2002, 95: 1584-1591.CrossRefPubMed Wright JR, Crooks D, Ellis PM, Mings D, Whelan TJ: Factors that influence the recruitment of patients to phase III studies in oncology: the perspective of the clinical research associate. Cancer. 2002, 95: 1584-1591.CrossRefPubMed
Metadata
Title
Removing barriers to participation in clinical trials, a conceptual framework and retrospective chart review study
Authors
Norma F Kanarek
Marty S Kanarek
Dare Olatoye
Michael A Carducci
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Trials / Issue 1/2012
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/1745-6215-13-237

Other articles of this Issue 1/2012

Trials 1/2012 Go to the issue